AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
deuruxolitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| Janus kinase inhibitors, antineoplastics | 5828 | 1513883-39-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Deuruxolitinib is a Janus kinase (JAK) inhibitor. In an in vitro kinase activity assay, deuruxolitinib had greater inhibitory potency for JAK1, JAK2 and TYK2 relative to JAK3. The relevance of inhibition of JAK enzymes to therapeutic effectiveness is not currently known.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 25, 2024 | FDA | Sun Pharmaceutical |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L04AF09 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Janus-associated kinase (JAK) inhibitors |
| FDA MoA | N0000190111 | Organic Anion Transporter 3 Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| FDA MoA | N0000190857 | Janus Kinase Inhibitors |
| FDA EPC | N0000190858 | Janus Kinase Inhibitor |
| FDA MoA | N0000193845 | Bile Salt Export Pump Inhibitors |
| FDA MoA | N0000193932 | Multidrug and Toxin Extrusion Transporter 2 K Inhibitors |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Related Drugs by ATC class:
L04AF Janus-associated kinase (JAK) inhibitors 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Alopecia areata | indication | 68225006 | DOID:986 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 8MG BASE | LEQSELVI | SUN PHARM INDS INC | N217900 | July 25, 2024 | RX | TABLET | ORAL | 10561659 | May 4, 2037 | TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA |
| EQ 8MG BASE | LEQSELVI | SUN PHARM INDS INC | N217900 | July 25, 2024 | RX | TABLET | ORAL | 12076323 | May 4, 2037 | TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA |
| EQ 8MG BASE | LEQSELVI | SUN PHARM INDS INC | N217900 | July 25, 2024 | RX | TABLET | ORAL | 11919907 | May 21, 2041 | TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA |
| EQ 8MG BASE | LEQSELVI | SUN PHARM INDS INC | N217900 | July 25, 2024 | RX | TABLET | ORAL | 12285432 | Aug. 11, 2042 | TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA |
| EQ 8MG BASE | LEQSELVI | SUN PHARM INDS INC | N217900 | July 25, 2024 | RX | TABLET | ORAL | 12364699 | Oct. 10, 2044 | TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 8MG BASE | LEQSELVI | SUN PHARM INDS INC | N217900 | July 25, 2024 | RX | TABLET | ORAL | July 25, 2029 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase JAK3 | Kinase | INHIBITOR | IC50 | 6.06 | DRUG LABEL | DRUG LABEL | |||
| Tyrosine-protein kinase JAK1 | Kinase | INHIBITOR | IC50 | 9.34 | DRUG LABEL | DRUG LABEL | |||
| Tyrosine-protein kinase JAK2 | Kinase | INHIBITOR | IC50 | 8.59 | DRUG LABEL | DRUG LABEL | |||
| Non-receptor tyrosine-protein kinase TYK2 | Kinase | INHIBITOR | IC50 | 7.31 | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEMBL4594381 | ChEMBL_ID |
| C000731752 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4043993 | VANDF |
| C5446729 | UMLSCUI |
| CHEBI:757870 | CHEBI |
| CHEMBL4594382 | ChEMBL_ID |
| 11622 | INN_ID |
| 2147706-60-1 | SECONDARY_CAS_RN |
| 72704611 | PUBCHEM_CID |
| 387949 | MMSL |
| 43013 | MMSL |
| d10205 | MMSL |
| 019809 | NDDF |
| 11410 | IUPHAR_LIGAND_ID |
| 0CA0VSF91Y | UNII |
| 2716557 | RXNORM |
| D11866 | KEGG_DRUG |
| 019811 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| LEQSELVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47335-108 | TABLET, FILM COATED | 8 mg | ORAL | NDA | 29 sections |